Chemomab Therapeutics (CMMB) Tops Q3 EPS by 4c

Chemomab Therapeutics (NASDAQ: CMMB) reported Q3 EPS of $0.02, $0.04 better than the analyst estimate of ($0.02).

For earnings history and earnings-related data on Chemomab Therapeutics (CMMB) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c